GRAMD1B

Across TCGA pan-cancer cohorts, GRAMD1B mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated GRAMD1B data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GRAMD1B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GRAMD1B expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

CCRCC and LUAD are the cancer types where GRAMD1B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.177	1.000	.036	7	view →
LUAD	OS	Median	II,III,IV	1.000	0.803	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

GRAMD1B–CCRCC (DFS)

Open the CCRCC breakdown →